Cadrenal Therapeutics, INC. (CVKD) — 10-Q Filings

10-Q Filings (6)

• Cadrenal's Losses Widen, Cash Dwindles Amid Going Concern Doubts — Nov 10, 2025 Risk: high
  Cadrenal Therapeutics, Inc. reported a net loss of $2,685,705 for the three months ended September 30, 2025, an increase from a net loss of $2,407,829 in the pr
• Cadrenal's Q2 Loss Widens to $4.5M Amid Tecarfarin Development — Aug 11, 2025 Risk: high
  Cadrenal Therapeutics, Inc. (CVKD) reported no revenue for the quarter ended June 30, 2025, consistent with its status as a clinical-stage pharmaceutical compan
• Cadrenal Therapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Cadrenal Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in Delaware with its principa
• Cadrenal Therapeutics Files Q3 2024 10-Q Report — Nov 7, 2024 Risk: low
  Cadrenal Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2024. The company, incorporated in Delaware, is involved
• Cadrenal Therapeutics Files Q2 2024 10-Q Report — Aug 7, 2024 Risk: medium
  Cadrenal Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2024. The company, incorporated in Delaware with its principal
• Cadrenal Therapeutics, Inc. Files 10-Q for Period Ended March 31, 2024 — May 9, 2024 Risk: low
  Cadrenal Therapeutics, Inc. (CVKD) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Cadrenal Therapeutics, Inc. filed a Form 10-Q for the quarterly

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX